Molecular Characterization and Therapeutic Management of Prostate Cancer

May 8, 2021

The clinical management of metastatic prostate cancer is improving at a rapid pace, increasingly influenced by the advancement in molecular characterization of this disease. In particular, the identification of driver mutations and delineation of the molecular signatures of have resulted in significant improvements in the array of treatment options for this disease and improved individualization of prognosis. There are still uncertainties regarding the management of early prostate cancer. This meeting will provide an opportunity to hear from leading national and international experts on how recently published data may change practice, some of which will have immediate clinical applications. Furthermore, each session will have multiple segments on novel emerging treatment paradigms likely to transform the care of metastatic prostate cancer in the near future.

This virtual conference is intended to propagate new information to augment the knowledge and clinical competence of the cancer care providers in the following areas:

  • Advances in the identification of molecular driver mutations that impact prognosis for patients with Metastatic Castration Sensitive Prostate Cancer (mCSPC)
  • Use of molecular treatments in metastatic prostate cancer
  • Discussion of immediate versus delayed systemic therapy for patients with biochemical (PSA) failure after definitive, local treatment
  • Role of molecular imaging (PET based imaging) to clarify staging

Target Audience

  • Oncologists
  • Residents/Fellows
  • NPs/PAs
  • Pharmacists
  • Nurses

Registration fees: 

Registration is free for healthcare providers who are NOT employees of ACCME defined ineligible companies.

If you are a healthcare provider involved in patient care and are not an employee of an ineligible company, please proceed to registration and select "non-industry learner" and your fee will reset to $0.00.

An ineligible company is any entity producing, marketing, re-selling, or distributing healthcare goods or services consumed by, or used on, patients with the exception of hospitals and facilities that provide direct care to patients. If you are an employee of an ineligible company, please select "industry representative" and pay the industry registration fee when registering for this conference. 

Any unpaid participation by industry professionals will be billed an additional $150 for a total of $356 per person. 

 

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Explain the nuances of the data regarding optimal timing of initiation of androgen deprivation therapy (ADT) for patients with biochemical failure
  • Review recent data on the use of genomic testing to define the prognosis of patients with mCSPC
  • Summarize genomic testing to select treatment for metastatic castration-resistant prostate cancer
  • Discuss the optimal use of molecular imaging tests

     

Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 2.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 2.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 2.00 Contact Hours.
Course opens: 
02/12/2021
Course expires: 
09/20/2021
Event starts: 
05/08/2021 - 7:30am PDT
Event ends: 
05/08/2021 - 11:30am PDT
Cost:
$1.00
All times are listed in Pacific Standard Time (PST)

May 8th, 2021

7:15 AM PST: Zoom Link Opens

7:15 AM to 7:30 AM PST: Attendance/Exhibit

7:30 AM to 7:45 AM PST: Introduction and discussion about the Binaytara Foundation – Dr. Binay Shah

7:45 AM to 8:00 AM PST: Welcome/Pre-test questions - Dr. Benjamin L. Maughan

8:00 AM to 8:25 AM PST: The role of molecular imaging (PET) as a diagnostic tool in prostate cancer Dr. Tanya Dorff

8:25 AM to 8:50 AM PST: Systemic therapy in biochemical recurrenceDr. Benjamin L. Maughan

8:50 AM to 9:00 AM PST: Discussion

9:00 AM to 9:30 AM PST: Break

9:30 AM to 9:55 AM PST: Updates in cellular and molecular testing to define prognosis and personalized therapyDr. Umang Swami

9:55 AM to 10:20 AM PST: Novel immune therapy approaches for metastatic prostate cancer: advances in systemic therapy – Dr. Ulka Vaishampayan

10:20 AM to 10:30 AM PST: Discussion

10:30 AM to 10:35 AM PST: Concluding remarks

This meeting is held virtually on Zoom. Register for the activity to participate.

Once you sign up, you will receive a confirmation email. However, you will not receive a zoom link via email to join this meeting.

You will need to log into the activity page to access the zoom link on the day of the meeting. The link will be accessible about 30 minutes before the meeting starts.

 

More faculty coming soon!

Benjamin Maughan, MD, PharmD

Assistant Professor of Medicine

Huntsman Cancer Institute, University of Utah

Learn More

Ulka Vaishampayan, MD, 

Professor of Medicine

University of Michigan

Learn More

Umang Swami, MD

Assistant Professor of Medicine

Huntsman Cancer Institute, University of Utah

Learn More

Tanya Dorff, MD

Associate Clinical Professor of Medicine

City of Hope

Learn More

 

Disclosure of Conflict of Interest:

No Members of this activity's planning committee or faculty have any relevant financial relationship with an ineligible entity with the exception of the following faculties:

  • Ulka Vaishampayan, M.D. :Research Support - BMS, Merck and Astellas Inc, Consulting and Honoraria - from BMS, Bayer, Pfizer, Merck, AAA, Alkermes and Exelixis

All relevant financial relationships of individuals in control of the content have been identified and mitigated.  

DISCUSSION OF OFF LABEL PRODUCTS:

If any part of this activity will include the discussion of unapproved or investigational products, faculty discussing those products will clearly identify the product as investigational or not approved. 

  • Umang SwamiI, M.D.: Only peer reviewed literature with regards to cellular or molecular testing.
  • Tanya Dorff, M.D.: Lu177-PSMA

The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians.

The Binaytara Foundation designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity meets the criteria for up to 2.0 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.


Nursing Contact Hours 

Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 2.0 Contact Hours.


ABSM Maintenance of Certificate Recognition Statement: 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 2.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 2.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 2.00 Contact Hours.

Please support this meeting by visiting our sponsors and exhibitors in the main exhibit breakout room during the exhibit presentations.

Please note that exhibit presentations are promotional materials separate from the accredited activities. These presentations are held in the exhibit breakout room during designated exhibit hours.

We encourage you to visit the main exhibit breakout room and each company's breakout rooms during exhibit and break hours. 

The following Exhibitors will be making exhibit presentations during the exhibit hours:

CompanyReps PresentingLink to Exhibit Materials and Prescribing information
   
   
   
   

 

Price

Cost:
$1.00
Please login or register to take this course.

Registration Fees:

This activity is free for all healthcare providers who are not employees of an ineligible entity. Please select "non-industry learner" when you are ready to register for the course, and the price will reset to $0. 

If you are employed by industry, you must pay a registration fee to participate in these meetings. Any unpaid registration by industry participants will be invoiced an additional $150 for a total of $356.

 

Cancellation Policy

You may cancel your enrollment at any time. No credits will be offered if you do not complete all required steps of this activity which include registration, participation in the live activity via Zoom, and completion of pre & post tests as well as course evaluations.

 

Refund Policy 

This activity is free for all healthcare providers who are not employees of an ineligible entity.

No refunds will be issued if you are unable to attend the live meeting after enrollment.

Required Hardware/software

This activitywill be held virtually on Zoom. You will need access to internet and a hardware such as a laptop or desktop computer or a mobile device with Zoom application installed.

For best audio-visual experience, please update your Zoom application before joining the meeting.